0.05Open0.05Pre Close0 Volume4 Open Interest12.00Strike Price0.00Turnover88.66%IV33.20%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0294Delta0.0165Gamma357.80Leverage Ratio-0.0055Theta-0.0003Rho-10.53Eff Leverage0.0031Vega
MediWound Stock Discussion
MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025
Tuesday, 17th December at 8:00 am
YAVNE, Israel, Dec. 17, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced it will host a virtual Key Opinion Leader (KOL) event on Wednesday, January 8, 2025, at 10:00 AM ET. T...
·3 mins ago
Mediwound Announces U.S. Food and Drug Administration Approval of Nexobrid® for the Treatment of Pediatric Patients With Severe Thermal Burns
No comment yet